Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

BBTX

Bambusa Therapeutics Inc

Last Close
16.00
Nov 02 • 3:59 PM ET Dollar change+1.01 Percentage change(6.74%)
Aftermarket Close
16.30
Aftermarket • 5:00 PM ET Dollar change+0.30 Percentage change(1.87%)
Overview Compare Financials Options Filings Dilution
Healthcare Biotechnology USA Small NASD
Index
-
Market Cap
796.19M
Enterprise Value
-
Income
-
Sales
-
Book/sh
-
Cash/sh
-
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
26
IPO
Oct 30, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
-
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
96.33%
Inst Trans
-
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
3.26%
SMA50
3.26%
SMA200
3.26%
Trades
Shs Outstand
8.01M
Shs Float
-
Short Float
-
Short Ratio
-
Short Interest
-
52W High
15.66 2.17%
52W Low
13.60 17.65%
Volatility
- -
ATR (14)
1.65
RSI (14)
-
Beta
-
Rel Volume
0.20
Avg Volume
2.20M
Volume
433,204
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
Perf YTD
7.53%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
14.99
Price
16.00
Change %
6.74%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Salvia Investment GmbH10% OwnerNov 02 '26Buy16.00375,0006,000,0009,264,301Nov 02 04:07 PM
Jeggle Helmut WolfgangDirectorNov 02 '26Buy16.00375,0006,000,0009,264,301Nov 02 04:06 PM
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
Chief Financial OfficerMr. Jonathan I. Lieber M.B.A.
Chief Operating OfficerMs. Crystal MacKay
Vice President of Corporate Development & StrategyMs. Melody Zhu Ph.D.
Vice President & Head of CMCMr. Wenbing Hu Ph.D.
SecretaryMs. Isabelle Muldner
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)